Anti-aggregatory prostanoids. Part II.
The mechanism of antiplatelet potency of prostanoids and pharmacological methods that regulate their endogenous release are discussed. In addition the role of antiaggregatory prostanoids in atherosclerosis and some clinical trials with prostanoids are reviewed.
D000818:Animals; D001161:Arteriosclerosis / Q000209:etiology; D001696:Biomechanical Phenomena; D002986:Clinical Trials as Topic; D005227:Fatty Acids / Q000494:pharmacology*; D006801:Humans; D010974:Platelet Aggregation / Q000187:drug effects*; D011466:Prostanoic Acids / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use
D005227:Fatty Acids; D011466:Prostanoic Acids